Lung Infection—A Public Health Priority

Harvard School of Public Health, Boston, Massachusetts, USA.
PLoS Medicine (Impact Factor: 14). 03/2006; 3(2):e76. DOI: 10.1371/journal.pmed.0030076
Source: PubMed

ABSTRACT The pervasive burden of lung infections receives proportionately little attention from the biomedical and public health communities, argues Mizgerd.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ceftazidime and the β-lactamase inhibitor avibactam constitute a new, potentially highly active combination in the battle against ESBL-producing bacteria. To determine possible clinical use, it is important to know pharmacokinetic profiles of the compounds, also related to each other in plasma and different compartments of infection in experimental animals and humans. We used a neutropenic murine thigh- and lung-infection model to study pharmacokinetics in plasma and epithelial lining fluid (ELF). Mice were infected with ca. 10(6) CFU of Pseudomonas aeruginosa intramuscularly per thigh or intra-nasally to cause pneumonia and given 8 different (single) subcutaneous doses of ceftazidime and avibactam in various combined concentrations, ranging from 1 to 128 mg/kg in two-fold increases. Concomitant samples of serum and bronchoalveolar lavage were taken for up to 12 time points until 6 h after administration. Pharmacokinetics of both compounds were linear and dose-proportional in plasma and ELF, independent of infection-type, with estimated half-lives (SD in plasma of ceftazidime 0.28 (0.02) h and avibactam 0.24 (0.04) h and volumes of distribution 0.80 (0.14) and 1.18 (0.34) L/kg. The ELF-plasma AUC ratio (SE) was 0.24 (0.03) for total and 0.27 (0.03) for unbound ceftazidime; for avibactam the ratios were 0.20 (0.02) and 0.22 (0.02), respectively. No pharmacokinetic interaction between ceftazidime and avibactam was observed. Ceftazidime and avibactam showed linear plasma pharmacokinetics independent of dose-combinations used or infection-site in mice. Assuming pharmacokinetic similarity in humans, this indicates that similar dose ratios of ceftazidime and avibactam could be used for different infection-types and sites of infection. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 02/2015; 59(4). DOI:10.1128/AAC.04627-14 · 4.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute bacterial pneumonia is a significant public health concern worldwide. Understanding the signals coordinating lung innate immunity may foster the development of therapeutics that limit tissue damage and promote host defense. We have previously shown that lung mRNA expression of the IL-6 family cytokine Oncostatin-M (OSM) is significantly elevated in response to bacterial stimuli. However, its physiological significance during pneumonia is unknown. Here we demonstrate that OSM is rapidly increased in the airspaces of mice following pulmonary infection with E. coli. Neutralization of OSM caused a substantial decrease in airspace neutrophils and macrophages. Interestingly, OSM blockade also caused a marked reduction in lung CXCL5 expression, whereas other closely related neutrophil chemokines, CXCL1 and CXCL2, were unaffected. Intratracheal administration of recombinant OSM was sufficient to recapitulate the effect on CXCL5 induction, associated with robust activation of the STAT3 transcription factor. Cell sorting revealed that OSM effects were specific to lung epithelial cells, including a positive feedback loop in which OSM may facilitate expression of its own receptor. Finally, in vitro studies demonstrated that STAT3 was required for maximal OSM-induced CXCL5 expression. These studies demonstrate a novel role for OSM during pneumonia as an important signal to epithelial cells for chemokine induction mediating neutrophil recruitment.
    American Journal of Respiratory Cell and Molecular Biology 02/2015; DOI:10.1165/rcmb.2014-0342OC · 4.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Excessive host inflammatory responses negatively impact disease outcomes in respiratory infection. Host-pathogen interactions during the infective phase of influenza are well studied, but little is known about the host’s response during the repair stage. Here, we show that influenza infection stimulated the expression of angiopoietin-like 4 (ANGPTL4) via a direct IL6-STAT3-mediated mechanism. ANGPTL4 enhanced pulmonary tissue leakiness and exacerbated inflammation-induced lung damage. Treatment of infected mice with neutralizing anti-ANGPTL4 antibodies significantly accelerated lung recovery and improved lung tissue integrity. ANGPTL4-deficient mice also showed reduced lung damage and recovered faster from influenza infection when compared to their wild-type counterparts. Retrospective examination of human lung biopsy specimens from infection-induced pneumonia with tissue damage showed elevated expression of ANGPTL4 when compared to normal lung samples. These observations underscore the important role that ANGPTL4 plays in lung infection and damage and may facilitate future therapeutic strategies for the treatment of influenza pneumonia.
    Cell Reports 02/2015; in press. DOI:10.1016/j.celrep.2015.01.011 · 7.21 Impact Factor

Preview (3 Sources)

1 Download
Available from